Exit this survey

Prime Therapeutics (Prime) has begun transitioning the management of its pharmacy claims to Express Scripts (ESI) as of April 1, 2020.  Prime has also recently announced the transition of Medicare Part D claims to occur as of January 1, 2021.  COA and the law firm of Frier Levitt are completing an investigation into how Prime, ESI and Prescription Benefit Managers (PBMs) are impacting cancer care, and in particular, how Prime and ESI may have violated applicable contractual requirements, as well as State and Federal law.  Your assistance is needed in this project to best understand, protect and assert your legal rights.  Please complete the survey below regarding Prime and ESI's role in caring for your cancer patients.

ESI has also not allowed many practice/cancer center pharmacies to participate in their commercial networks. Where they do allow practice/cancer center pharmacies to participate they reimburse at rates many times that are below cost. Please complete the survey in full so that Frier Levitt can appropriately provide feedback to each of you on your rights under the law.

DISCLAIMER: The collection, if any, of what may be deemed competitively-sensitive information serves the sole purpose of evaluating the legal and/or governmental lobbying rights of each provider under the law, will remain undisclosed and will not be exchanged with or transmitted to other providers.

Question Title

* 1. Practice/Team Information

Question Title

* 2. Are you contracted with Prime Therapeutics in any way?

Question Title

* 3. What type on contracts do you have with Prime Therapeutics? (Check all that apply)

Question Title

* 4. Check the option that applies:

Question Title

* 5. What type of network are you in with Prime Therapeutics?

Question Title

* 6. Check the option that applies:

T